Pinealon vs Vesilute
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
- Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
- Half-Life
- Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ, Oral, Intranasal
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5–10 mg (oral) or 50–100 mcg (SC)
- 10 mg per day
- Frequency
- Once daily for 10 days
- Daily for 10–30 days
- Key Benefits
- Neuroprotection against oxidative stress and hypoxia
- Promotes neuronal regeneration and repair
- Improves memory and cognitive function
- Enhances sleep quality via melatonin regulation
- Anti-aging effects on brain cells
- May slow cognitive decline in neurodegeneration
- Improves cerebrovascular circulation
- Reduces neuroinflammation
- Supports retinal photoreceptor cell function and survival
- May slow progression of age-related macular degeneration
- Reduces retinal cell apoptosis from oxidative stress and aging
- Anti-aging effects on retinal pigment epithelium
- Potential support in diabetic retinopathy management
- Preserves visual acuity with aging
- Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
- Side Effects
- Excellent safety profile in clinical use
- Rare: mild drowsiness
- Transient mild headache at initiation
- Injection site reaction (SC)
- Generally well tolerated
- Mild injection site reactions
- No significant ocular adverse events reported at standard doses
- Stacks With
- —
- —